Drug Trial Radar · NCT05818085
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Aug 11, 2023
Primary completion
Jan 30, 2025
Study completion Mar 30, 2025
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
Conditions
- Gout
Interventions
ABP-671Drug
Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
AllopurinolDrug
Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
PlaceboOther
ABP-671 matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve serum uric acid (sUA) levels <6.0 mg/dL (<0.360 mmol/L)Time frame: Week 28
Locations
57 sites in 5 countries. Site status is shown where the registry gives one.
Alliance for Multispecialty Research
Tempe, Arizona
Tucson Neuroscience Research, LLC
Tuscon, Arizona
Anaheim Clinical Trials (Cenexel ACT)
Anaheim, California
Center for Clinical Trials of Sacramento
Sacramento, California
Access Research Institute
Brooksville, Florida
Nature Coast Clinical Reasearch
Crystal River, Florida
JY Research Institute Inc.
Cutler Bay, Florida
Accel Clinical Research Site
DeLand, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Accel Research Sites Network - St. Pete-Largo Clinical Research Unit
Largo, Florida
A & D Doctor Center
Miami, Florida
Bioclinical Research Alliance
Miami, Florida
Cordova Research Institute
Miami, Florida
Century Research LLC
Miami, Florida
ITB Research
Miami, Florida
Combined Research Orlando Phase I-IV
Orlando, Florida
New Horizons Research
Palmetto Bay, Florida
Advanced Clinical Research of Atlanta
Atlanta, Georgia
Centricity Research
Columbus, Georgia
Alliance for Multispecialty Research, LLC.
Newton, Kansas
DelRicht Research
New Orleans, Louisiana
AMR
New Orleans, Louisiana
Annapolis Internal Medicine/CCT Research
Annapolis, Maryland
DelRicht Research of Gulfport
Gulfport, Mississippi
Quality Clinical Research, Inc
Omaha, Nebraska
Santa Rosa Medical Center
Las Vegas, Nevada
Inspire Santa Fe Medical Group
Santa Fe, New Mexico
OnSite Clinical Solutions
Salisbury, North Carolina
DelRicht Research
Tulsa, Oklahoma
Altoona Center for Clinical Research
Duncansville, Pennsylvania
ClinSearch
Chattanooga, Tennessee
Medical Care/CCT
Elizabethton, Tennessee
PanAmerican Clinical Research, LLC
Brownsville, Texas
Quality Research Inc.
San Antonio, Texas
Centricity Research
Suffolk, Virginia
Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
Emeritus Research Sydney
Botany, New South Wales, Australia
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia
A R Houston Medical Pty Ltd
Kippa-Ring, Queensland, Australia
Emeritus Research Melbourne
Camberwell, Victoria, Australia
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.